JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marrannes, R.
Right arrow Articles by De Prins, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marrannes, R.
Right arrow Articles by De Prins, E.

Vol. 295, Issue 2, 531-545, November 2000


Site of Action of Lubeluzole on Voltage-Sensitive Ca2+ Channels in Isolated Dorsal Root Ganglion Cells of the Rat: Influence of pH

Roger Marrannes and Erik De Prins

Central Nervous System Discovery Research, Janssen Research Foundation, Beerse, Belgium

    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Besides other pharmacological effects, the neuroprotective compound lubeluzole blocks low-voltage-activated (iLVA) and high-voltage-activated (iHVA) calcium channel currents. We investigated the site of action of lubeluzole on Ca2+ channels in isolated dorsal root ganglion cells of the rat, using whole-cell voltage clamp. Experiments with extracellular application of 3 µM lubeluzole (pKa = 7.6) at different values of extracellular pH suggest that the protonated form of lubeluzole contributes to the block of iLVA and iHVA from the extracellular side. The partial block of iLVA and iHVA by 3 µM lubeluzole at extracellular pH 9 and intracellular pH (pHi) 9 indicates that the uncharged form of lubeluzole (L) may contribute to the block as well. The voltage-dependent acceleration of the apparent inactivation of iHVA by lubeluzole was much more pronounced at lower pHi, which is consistent with membrane penetration of L and an open channel block of iHVA by the prononated form of lubeluzole acting from the intracellular side. Decreasing pHi induced a negative shift of the half-inactivation potential of iLVA and increased the lubeluzole-induced block of iLVA. Experiments with extracellular or intracellular application of a quaternary ammonium derivative of lubeluzole (R133121), which was less potent than lubeluzole, support the above conclusions on the side of action of lubeluzole. Application of lubeluzole via the patch pipette affected iLVA and iHVA only minimally compared with extracellular application, probably partly due to efflux of L through the cell membrane. These experiments suggest that lubeluzole blocks Ca2+ channels from both the extracellular and the intracellular side.

    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Lubeluzole, the (+)-S-enantiomer of a benzothiazole derivative (Fig. 1), has a neuroprotective action in animal models of focal and global ischemia, in which it reduces sensorimotor deficits and the infarct volume (for review, see De Ryck, 1997). Experiments on neuronal cultures have shown that lubeluzole inhibits glutamate-induced nitric oxide-related neurotoxicity and that it blocks neurotoxicity induced by nitric oxide donors (Lesage et al., 1996; Maiese et al., 1997). Although a phase II clinical study seemed promising, a clear neuroprotective effect could not be demonstrated in phase III studies in patients with acute ischemic stroke (Diener, 1998).

Lubeluzole also affects ion channels. It blocks the fast sodium channel and antagonizes veratridine-induced neurotoxicity (Osikowska-Evers et al., 1995; Ashton et al., 1997). Lubeluzole blocks the transient low-voltage-activated Ca2+ channel current (iLVA or T-current) (Marrannes et al., 1998b) and the high-voltage-activated Ca2+ channel current (iHVA) in a concentration-, voltage-, and frequency-dependent manner (Hernández-Guijo et al., 1997; Marrannes et al., 1998b). The time needed for the block of Ca2+ channels to reach steady state suggests that lubeluzole penetrates the cell or cell membrane, or that another slow intracellular process is implied.

In the present study, we investigated the site of action of lubeluzole on Ca2+ channels. The question was addressed whether lubeluzole blocks Ca2+ channels from the extracellular or intracellular side and whether the protonated form of lubeluzole (HL+) or its uncharged basic form (L) produces the effects. To answer these questions, two methods were used and compared: 1) variation of the concentration of HL+ and L at both sides of the cell membrane, by testing the effect of lubeluzole (pKa = 7.6) at different values of extracellular pH (pHo) and intracellular pH (pHi); and 2) application of lubeluzole and a permanently charged methyl iodide quaternary derivative of lubeluzole (R133121) (Fig. 1) via the extracellular solution or via the patch pipette.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Chemical structure of lubeluzole [(+)-(S)-4-[(2-benzothiazolyl)methylamino]-alpha -[(3,4-difluorophenoxy)methyl]-1-piperidineethanol] and its methyl iodide quaternary derivative R133121 (TRANS, S) 4-[(2-benzothiazolyl)methylamino]-alpha -[(3,4-difluorophenoxy)methyl]-1-methyl-1-piperidineethanol] iodide.

Variation of pHo and pHi by itself also influences Ca2+ channels. The activation and inactivation curves of iHVA shift positively after a reduction in pHo (Krafte and Kass, 1988; Tombaugh and Somjen, 1996; Zhou and Jones, 1996) but negatively after a reduction in pHi (Kaibara and Kameyama, 1988; Tombaugh and Somjen, 1997), as a consequence of a change in surface charges (Hille, 1992). In addition, protons can influence the channel conductance by other mechanisms (Iijima et al., 1986; Krafte and Kass, 1988; Prod'Hom et al., 1989; Zhou and Jones, 1996) and iHVA is blocked by a reduction in pHo (Tombaugh and Somjen, 1996; Zhou and Jones, 1996) or pHi (Kaibara and Kameyama, 1988; Tombaugh and Somjen, 1997) and iHVA increases after an alkaline change in pHo and/or pHi. Although iLVA is very sensitive to pHo and decreases when pHo falls, it was found to be insensitive to a change in pHi (Tytgat et al., 1990; Tombaugh and Somjen, 1997). The study of the influence of pHo and pHi on the block of iLVA and iHVA by lubeluzole is also relevant to estimating the effect of a compound such as lubeluzole in ischemic situations, which are accompanied by changes in pHo and pHi (Lipton, 1999). Part of this study has been reported in abstract form (Marrannes et al., 1998a).

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Cell Preparation. DRG neurons were isolated from male Wistar rats (250 g) as described previously (Marrannes et al., 1998b), with some modifications. Briefly, DRGs were digested at 37°C in 1 ml of 0.5% collagenase medium for 30 min, to which 1 ml of 0.25% trypsin medium was then added, and digestion was allowed to continue for a further 30 min. The collagenase medium contained 0.5% collagenase (Boehringer Mannheim, Mannheim, Germany), and 120 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 3 mM D-glucose, 0.1 mM CaCl2, 19.7 mM NaHCO3, and 31.4 mM HEPES at pH 8. The trypsin medium contained 0.25% trypsin (Life Technologies, Merelbeke, Belgium), and 136.7 mM NaCl, 2.7 mM KCl, 16.3 mM Na2HPO4, and 1.5 mM KH2PO4. After washing and trituration of the dorsal root ganglia, purification of the cells in a Percoll gradient and removal of nonneuronal cells, the DRG cells were seeded in the center of Petri dishes that had previously been coated with poly(L-lysine) at 100 µg/ml (1 h) and then with laminin at 10 µg/ml (4 h). The cells were incubated in DMEM-fetal calf serum at 37°C in a humidified atmosphere (95% air, 5% CO2) for 4 h. DMEM-fetal calf serum is DMEM to which 10% fetal calf serum and 6 g/l D-glucose were added, together with 0.3 mM L-cysteine, 0.4 mM L-alanine, 0.4 mM L-asparagine, 0.4 mM L-aspartic acid, 0.4 mM L-proline, and 0.4 mM L-glutamic acid as amino acid supplements. Then 4 ml of the HEPES-buffered solution used to perfuse the experimental chamber (see below) was added to the medium of each Petri dish, and the cells were stored at 4°C to retard the decline of iLVA. The cells were used for experiments on the day of isolation and the following day. Except when a different cell size is specified in the text, we used medium-sized DRG cells (35-40 µm) having a large LVA Ca2+ channel current (Scroggs and Fox, 1992).

Electrophysiological Recording. Whole-cell voltage clamp (Hamill et al., 1981) was performed as described previously (Marrannes et al., 1998b). The electrode resistance ranged from 1.5 to 2.5 MOmega when measured in the bath. After the patch had been broken, the cells were allowed to equilibrate with the contents of the electrode for 5 min before stimulation, except in the experiments in which lubeluzole, R133121, or the corresponding amount of DMSO was applied via the microelectrode.

The holding potential (HP) was -100 mV. As a standard protocol to test the effect of lubeluzole on Ca2+ channels, every 30 s a 200-ms test pulse to -50 mV was given, to elicit and inactivate iLVA, followed by a 155-ms pulse to -20 mV to activate iHVA. To eliminate contaminating current through HVA Ca2+ channels, iLVA was quantified as the difference between the peak inward current and the current at the end of the test pulse at -50 mV. To correct for drift or run-down of the Ba2+ currents, the time courses of iLVA and iHVA were fitted to a double exponential for the 5-min period in which the control solution without lubeluzole was used, and they were extrapolated for the remainder of the experiment. Division of each measured current amplitude by the value of the corresponding calculated curve obtained by fitting, at the same time point, yielded the current ratios rLVA, rHVApeak, and rHVAend used in Figs. 7 and 8.

Solutions. Lubeluzole and R133121 (both from Janssen Pharmaceutica, Beerse, Belgium) were prepared in 10 mM stock solutions in DMSO. The concentration of DMSO in the control solutions was always the same as in the corresponding solutions with one of these compounds.

The internal pipette solution contained 100 mM CsCl, 10 mM EGTA, 1 mM MgCl2, 3 mM magnesium-ATP, 0.3 mM Tris-GTP, and 40 mM HEPES and was adjusted to pH 7.2 with CsOH. In the experiments with intracellular application of lubeluzole or R133121, the compound (or the corresponding amount of DMSO) was added to this pipette solution. In some experiments the pH of the pipette solution (pHi) was adjusted to 6, 6.6, or 9, and 40 mM HEPES was replaced by 10 mM MES (pKa = 6.1), N,N-bis[2-hydroxyethyl]-2-amino-ethanesulfonic acid (pKa = 7.1), or 3-[(1,1-dimethyl-2-hydroxyethyl)amino]-2-hydroxypropanesulfonic acid (pKa = 9), respectively, and then the CsCl concentration used was 122 mM CsCl (instead of 100 mM).

The external solutions contained 2 mM BaCl2, 135 mM tetraethylammonium chloride, 0.5 µM tetrodotoxin, 10 mM HEPES and were adjusted to pH 7.4 with tetraethylammonium hydroxide. In some experiments the extracellular pH (pHo) was 6, 6.8, or 9, and then the 10 mM HEPES was replaced by 10 mM MES, N,N-bis[2-hydroxyethyl]-2-amino-ethanesulfonic acid, or 3-[(1,1-dimethyl-2-hydroxyethyl)amino]-2-hydroxypropanesulfonic acid buffer, respectively. Because Ba2+ was used in the extracellular solution instead of Ca2+, the current through Ca2+ channels was carried by Ba2+.

The DRG cell was superfused with the control or test solutions by means of a gravity-driven puffer system placed at a distance of 0.3 mm from the cell. This superfusion system changed the extracellular solution in the immediate vicinity of the tested cell under study in less than a second (Marrannes et al., 1998b).

Variation of Extracellular and Intracellular pH to Change the Extracellular and Intracellular Concentration of the Protonated and Basic Form of Lubeluzole. Lubeluzole is a weak base (pKa = 7.6). The fraction of the extracellular lubeluzole concentration in the HL+ and in the L form can be calculated as follows:
[<UP>HL<SUP>+</SUP></UP>]<SUB><UP>o</UP></SUB>/[<UP>T</UP>]<SUB><UP>o</UP></SUB>=[<UP>H<SUP>+</SUP></UP>]<SUB><UP>o</UP></SUB>/(K<SUB><UP>a</UP></SUB>+[<UP>H<SUP>+</SUP></UP>]<SUB><UP>o</UP></SUB>) (1)

[<UP>L</UP>]<SUB><UP>o</UP></SUB>/[<UP>T</UP>]<SUB><UP>o</UP></SUB>=K<SUB><UP>a</UP></SUB>/(K<SUB><UP>a</UP></SUB>+[<UP>H<SUP>+</SUP></UP>]<SUB><UP>o</UP></SUB>) (2)
where [T]o is the total extracellular lubeluzole concentration ([T]o = [HL+] o + [L] o), Ka is the dissociation constant of HL+, and [H+]o is the extracellular proton concentration. Part of L that penetrates the cell membrane is protonated in the cell to HL+ as a function of its Ka and pHi. If HL+ does not cross the cell membrane and L diffuses only passively through the cell membrane and if lubeluzole does not disappear rapidly via the electrode or metabolism, one can assume that in steady state the intracellular concentration of L ([L]i) will approach [L]o or the following:
[<UP>L</UP>]<SUB><UP>i</UP></SUB>=[<UP>L</UP>]<SUB><UP>o</UP></SUB>. (3)
Because
K<SUB><UP>a</UP></SUB>=[<UP>H<SUP>+</SUP></UP>]<SUB><UP>i</UP></SUB>×[<UP>L</UP>]<SUB><UP>i</UP></SUB>/[<UP>HL<SUP>+</SUP></UP>]<SUB><UP>i</UP></SUB> (4)
combining eqs. 2, 3, and 4 yields the following:
[<UP>HL<SUP>+</SUP></UP>]<SUB><UP>i</UP></SUB>/[<UP>T</UP>]<SUB><UP>o</UP></SUB>=[<UP>H<SUP>+</SUP></UP>]<SUB><UP>i</UP></SUB>/(K<SUB><UP>a</UP></SUB>+[<UP>H<SUP>+</SUP></UP>]<SUB><UP>o</UP></SUB>) (5)
This is valid on the condition that eq. 3 is true. The calculated values for [HL+]o/[T]o, [L]o/[T]o, and [HL+]i/[T]o at different values of pHo and pHi are shown in Table 1.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
Influence of pHo and pHi on the equilibrium concentrations of the protonated and uncharged form of lubeluzole at both sides of the cell membrane

Lubeluzole is a weak base (pKa = 7.6). The third and fourth columns give the fraction of the total extracellular lubeluzole concentration that is in the protonated form ([HL+]o/[T]o) and in the uncharged form ([L]o/[T]o). If it is assumed that after transmembrane equilibration [L]i equals [L]o, the ratio of the intracellular HL+ concentration to the total extracellular lubeluzole concentration can be calculated ([HL+]i/[T]o) (under Materials and Methods).

As can be deduced from eqs. 1, 2, and 5 and Table 1, varying pHo at constant pHi makes it possible to vary [HL+]o relative to [L]o and [HL+]i. However, because the ratio [L]/[HL+]i remains constant after a variation in pHo at constant pHi (eqs. 2 and 5), an effect via L (extracellular or intracellular or in the cell membrane) cannot be distinguished from an effect via intracellular HL+ through varying pHo alone. In contrast, varying pHi at constant pHo allows this distinction; through varying pHi one can vary [HL+]i independently of [L] and [HL+]o and determine the relative importance of intracellular HL+ for the observed effects on iLVA and iHVA. Equation 5 also predicts that through varying pHi much greater changes in [HL+]i can be induced than through varying pHo (Table 1). A low pHi even enables accumulation of HL+ in the cell to a concentration higher than [T]o. Because the completely intracellular HL+ ions equilibrate with the HL+ sitting with an uncharged part of the molecule within the cell membrane and protruding with the charged nitrogen atom into the aqueous intracellular solution, it can be expected that such partly intracellular HL+ would also be more concentrated within the membrane at a lower pHi.

Statistical Analysis. The data are expressed as mean ± S.D., except in Figs. 6 and 8, where S.E. is used. The difference between groups was evaluated by means of the two-sided Student's t test for independent samples. The difference between the values of the inactivation parameters before and after application of lubeluzole was evaluated with a two-sided paired t test (Fig. 6). The dependence of a measured variable on pHi was evaluated by means of a two-sided Jonckheere-Terpstra test for ordered alternatives. Values of P < .05 were considered to indicate statistical significance.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Extracellular Application of Lubeluzole. Figure 2 illustrates the effects of 3 µM lubeluzole at pHo 7.4, with a pipette solution of pHi 7.2. First the activation of iHVA was investigated in the control solution (Fig. 2A). Thereafter, a constant pulse sequence with test pulses to -50 and -20 mV was given every 30 s to activate iLVA and iHVA, respectively, and 3 µM lubeluzole was applied via the extracellular solution (Fig. 2B). Lubeluzole induced a rapid decrease of iLVA and iHVA, followed by a gradual further decrease for at least 5 min. Thereafter, the activation of iHVA was tested again (Fig. 2C). At -30 mV lubeluzole accelerated the apparent inactivation of iHVA and this was even more pronounced at -20 mV. The observation that lubeluzole accelerates the apparent inactivation of iHVA more at test potentials at which iHVA is more activated is consistent with an open channel block of iHVA by lubeluzole. Lubeluzole did not decrease the time constant of inactivation of iLVA, in contrast to that of iHVA.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Influence of extracellular application of lubeluzole at pHo 7.4 and pHi 7.2. A, activation of iHVA in the control solution. From a -100-mV HP, a 200-ms test pulse to -50 mV was given to elicit and inactivate iLVA nearly completely. Thereafter, 155-ms test pulses varying from -50 to +10 mV were given to activate iHVA. The sweep interval was 20 s. B, transition from the control solution to 3 µM lubeluzole. Every 30 s the shown pulse sequence was given. The last sweep in the control solution is shown together with the first 10 sweeps in the presence of 3 µM lubeluzole. Lubeluzole was applied immediately after the last sweep in the control solution. C, activation of iHVA after 5-min application of 3 µM lubeluzole. D, I-V relationships of iHVA derived from the sweeps in A and C. Filled symbols: peak inward current. Unfilled symbols: current at the end of the 155-ms test pulse.

Influence of pHo on the Block of iLVA and iHVA by Lubeluzole. To see mainly the contribution of extracellular HL+ to the block of iLVA and iHVA and to a lesser extent the contribution of L and intracellular HL+, the influence of lubeluzole was tested at pHo 6 (Table 1). A decrease in pHo reduced iLVA and iHVA (Fig. 3A). At 30 s after extracellular application of 3 µM lubeluzole at constant pHo 6 there was a clear inhibition of iLVA and a much smaller relative block of iHVA, which changed only little thereafter (n = 5) (Fig. 3B). When lubeluzole was superfused only 15 s before the next pulse sequence (given every 30 s), there was already some block of iLVA and iHVA but this block was clearly more extensive 30 s later, after which it was approximately stable (n = 5) (Fig. 3C). The equilibration time of the effect of lubeluzole at pHo 6 was shorter than that at pHo 7.4 (Fig. 2B), probably because it reflects the rapid equilibration of the extracellular effect of HL+ on iLVA and iHVA, given the lower [L] and reduced penetration of L and intracellular accumulation of HL+ at pHo 6. It is remarkable that 3 µM lubeluzole accelerated either very little or not at all the apparent inactivation of iHVA at pHo 6, which indicates that extracellular HL+ is not sufficient to produce this acceleration. A large delayed acid-induced inward current (Waldmann et al., 1999), starting 2.1 ± 2.3 min (mean ± S.D., n = 29) after the decrease in pHo, terminated the experiment prematurely in most cells at pHo 6. 


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   Influence of pHo on the effects of lubeluzole on iLVA and iHVA. A, sweeps recorded at pHo 7.4 and 30 s after switching to pHo 6 in the absence of lubeluzole. B, block of iLVA and iHVA by 3 µM lubeluzole at constant pHo 6. Lubeluzole was applied immediately after the sweep in the control solution. Sweeps are shown every 30 s until 3.5 min after application of lubeluzole. Same cell as in A. Note the difference in scale. C, in another cell 3 µM lubeluzole was given 15 s after the control sweep and 15 s before the next sweep. Sweeps are shown in the control solution and 15, 45, and 75 s after application of lubeluzole. D, sweeps recorded at pHo 7.4 and 30 s after switching to pHo 9 in the absence of lubeluzole. Same cell as in E, F, and H. E, at constant pHo 9 the block of iLVA and iHVA by 3 µM lubeluzole was more progressive than at pHo 6 (compare E with B). F, sweeps are shown after 5-min equilibration in 3 µM lubeluzole at pHo 9 and 30 s after pHo was lowered to 7.4 while the external lubeluzole concentration was kept constant at 3 µM. G, time course of the experiment shown in B. ILVA is quantified as the difference between the peak inward current and the current at the end of the test pulse to elicit iLVA (at -40 mV); iHVApeak and iHVAend are the peak inward current and the current at the end of the test pulse to elicit iHVA, respectively. H, time course of the experiment shown in D to F.

At pHo 9 [HL+]o was 16 times lower than at pHo 7.4 and the contribution of extracellular HL+ to the block of iLVA and iHVA was reduced. On the other hand, [L] and the predicted steady-state [HL+]i were 2.5 times higher than at pHo 7.4 (Table 1). This suggests that application of 3 µM lubeluzole at pHo 9 may show mainly the effects of incorporation of the uncharged form of lubeluzole into the membrane, its penetration into the cell, and the effect of the intracellular HL+. Switching from pHo 7.4 to pHo 9 increased iLVA and iHVA (Fig. 3D). After application of 3 µM lubeluzole at pHo 9 there was a more gradual decrease in iLVA and iHVA (Fig. 3, E and H) than at pHo 6 (Fig. 3, B and G). Five minutes after application of lubeluzole at pHo 9/pHi 7.2, iLVA was blocked by 58 ± 3%, the peak amplitude of iHVA (iHVApeak) by 32 ± 4%, and the amplitude at the end of the 155-ms test pulse to -20 mV (iHVAend) by 61 ± 4% (mean ± S.D., n = 6). Remarkably, lubeluzole clearly accelerated the apparent inactivation of iHVA at pHo 9 (Fig. 3E), in contrast to what was observed at pHo 6, which indicates that this acceleration does not correlate with [HL+]o.

After a 5-min equilibration with 3 µM lubeluzole at pHo 9, pHo was switched again to pHo 7.4 in the continuous presence of lubeluzole (Fig. 3, F and H). The percentage change of the amplitude of iLVA after this switch (Fig. 3F) was larger than that after the inverse change in pHo from 7.4 to 9 in the absence of lubeluzole (Fig. 3D). This was seen in all tested cells (n = 6). This suggests that, in the presence of lubeluzole, the sudden extracellular replacement of L by HL+ due to the change in pHo increased the relative effect of the pHo changes on iLVA, and consequently that extracellular HL+ blocks iLVA more than L. To estimate mainly the effect of extracellular HL+ before cellular penetration of L, the time course of iLVA after the switch from pHo 9 to pHo 7.4 (Fig. 3H) was fitted to a polynomial and extrapolated (30 s back) to the moment of the change in pHo. The same was done for the time course of iLVA after the switch from pHo 7.4 to pHo 9 in the absence of lubeluzole.

The quotient QiLVA = RiLVA(lubeluzole)/RiLVA(control) was calculated. RiLVA(lubeluzole) is the amplitude of iLVA at pHo 7.4 in the presence of 3 µM lubeluzole and extrapolated back to the moment of the change from pHo 9 to pHo 7.4, divided by the measured iLVA just before this pHo change. RiLVA(control) is the measured iLVA in the control solution at pHo 7.4, divided by iLVA at pHo 9, and extrapolated to the moment of the change from pHo 7.4 to pHo 9. The quotient QiLVA worked out to 0.72 ± 0.04 (mean ± S.D., n = 6), meaning that the relative effect of such a pHo change on iLVA was greater in the presence than in the absence of lubeluzole. In time-matched control experiments in which the same sequence of pHo changes was induced but without application of lubeluzole, QiLVA worked out to 1.04 ± 0.18 (n = 6), which was significantly different from QiLVA in the lubeluzole experiments (P < .01, two-sided t test for independent samples). This indicated a contribution of extracellular HL+ to the inhibition of iLVA by lubeluzole because rapid replacement of L by HL+ appeared to decrease iLVA further. An analogous quotient, QiHVA, calculated for iHVApeak in lubeluzole experiments (0.98 ± 0.09, n = 6) was not significantly different from QiHVA in time-matched control experiments (1.03 ± 0.02, n = 6). Consequently, we did not distinguish a greater extracellular effect on iHVApeak by HL+ than by L with this method.

The switch from pHo 9 to pHo 7.4 in the presence of 3 µM lubeluzole produced no sudden acceleration of the apparent inactivation of iHVA (n = 6), although there was a 16-fold increase in extracellular HL+. This corroborates our hypothesis that the acceleration of the apparent inactivation of iHVA by lubeluzole is not due to an extracellular effect of HL+, but rather to an effect of L and/or an effect of intracellular HL+.

Influence of Intracellular pH on the Block of iHVA by Lubeluzole. To distinguish the contribution of intracellular HL+ from that of L, the effect of lubeluzole was tested at different values of pHi, but at a constant pHo of 7.4. Figure 4 shows the effect of extracellular application of 3 µM lubeluzole (pHo 7.4) with a pipette solution of pHi 9. At pHi 9 the intracellular equilibrium concentration of HL+ is expected to be 65 times lower than at pHi 7.2, whereas [HL+]o, [L]o, and [L]i are unchanged (Table 1). If the acceleration of the apparent inactivation of iHVA by lubeluzole is due to an effect of HL+ from the intracellular side, then this acceleration is predicted to be much less at pHi 9 than at pHi 7.2, which indeed was observed (compare Figs. 2 and 4). At pHi 6 [HL+]i is expected to be 15.8 times higher than at pHi 7.2 (Table 1). Accordingly, at pHi 6 lubeluzole induced a much faster voltage-dependent acceleration of the apparent inactivation of iHVA than at pHi 7.2 (compare Figs. 2 and 5). The block of iHVA and the acceleration of the apparent inactivation of iHVA by lubeluzole are thus strongly dependent on pHi and much more pronounced at lower pHi, at which [HL+]i would be expected to be higher.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Influence of 3 µM lubeluzole on the activation of iHVA at pHi 9 (and pHo 7.4). A, activation of iHVA in the control solution. B, transition from the control solution to 3 µM lubeluzole. Every 30 s the shown pulse sequence was given. The last sweep in the control solution is shown together with the first 10 sweeps in the presence of 3 µM lubeluzole. C, activation of iHVA after 5-min application of lubeluzole. D, I-V relationships of iHVA derived from the sweeps in A and C. Filled symbols: peak inward current. Unfilled symbols: current at the end of the 155-ms test pulse.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Influence of 3 µM lubeluzole at pHi 6 (and pHo 7.4). A, activation of iHVA in the control solution. B, transition from the control solution to 3 µM lubeluzole. Every 30 s the shown pulse sequence was given. The last sweep in the control solution is shown together with the first 10 sweeps in the presence of 3 µM lubeluzole. C, activation of iHVA after 5-min application of lubeluzole. D, I-V relationships of iHVA derived from the sweeps in A and C. Filled symbols: peak inward current. Unfilled symbols: current at the end of the 155-ms test pulse.

A comparison of Figs. 2D, 4D, and 5D shows that in the absence of lubeluzole intracellular acidosis shifted the activation curve of iHVA negatively, whereas intracellular alkalosis shifted it positively, probably through an effect of pHi on intracellular surface charges (Kaibara and Kameyama, 1988; Tombaugh and Somjen, 1997). The voltage of the maximal inward current of the fitted activation curve of iHVApeak in the absence of lubeluzole was -27.0 ± 3.2 mV at pHi 6 (mean ± S.D., n = 6), -16.7 ± 4.2 mV at pHi 7.2 (n = 6), and -11.8 ± 3.3 mV at pHi 9 (n = 6), 10 min after the whole-cell configuration was established. Therefore, we tested whether pHi-dependent shifts in gating of iHVA could explain the influence of pHi on the degree of acceleration of the apparent inactivation of iHVA by lubeluzole. We could not obtain an acceleration of the apparent inactivation of iHVA as observed at pHi 7.2 (with a -100-mV HP, a -50-mV prepulse, and a -20-mV test pulse) by using a less negative HP (-90 or -80 mV), prepulse (-40 or -45 mV), and/or test pulse (-10 mV) at pHi 9 to compensate for the positive shift in activation and inactivation curves of Ca2+ channels at pHi 9 (n = 3). Similarly, with the use of a more negative HP (-110 or -120 mV instead of -100 mV) and/or a more negative prepulse to elicit and inactivate iLVA (-60 or -70 mV instead of -50 mV) to compensate for a negative shift in Ca2+ channel gating at pHi 6, the block of iHVA, and the acceleration of the apparent inactivation of iHVA were still much greater at pHi 6 than at pHi 7.2 (n = 3). The greater effect of lubeluzole on iHVA at lower pHi can thus not be explained by pHi-dependent gating shifts of iHVA but is consistent with a block of iHVA by intracellular HL+. Nor is the more extensive block of iHVA by lubeluzole at pHi 6 due to the presence of MES buffer in the electrode solution instead of HEPES buffer because the same degree of block of iHVA was obtained when the pipette solution contained 10 mM MES at pHi 7.2 (n = 3) as with HEPES in the electrode solution at pHi 7.2.

A much more extensive block of iHVA by lubeluzole at pHi 6 than at pHi 7.2 was not only seen with the normally used DRG cells (diameter 35-40 µm) but also with smaller DRG cells (24.5 ± 2.5 µm, mean ± S.D., n = 4), which are reported to express proportionally more L-type Ca2+ currents (Scroggs and Fox, 1992).

Influence of pHi on the Inactivation of iLVA and Block of iLVA by Lubeluzole. At constant pHo 7.4, the block of iLVA by lubeluzole was smaller at pHi 9 than at pHi 7.2 and even more extensive at pHi 6 (Figs. 2B, 4B, 5B, and 8). This might be due to an intracellular contribution of HL+ to the inhibition of iLVA. Alternatively, this could be partly a consequence of possible pHi-dependent shifts of the inactivation curve of iLVA. The inactivation of iLVA was therefore studied at different values of pHi, in the absence and presence of 1 µM lubeluzole (Fig. 6). In the absence of lubeluzole, the inactivation curve was clearly shifted to the left by intracellular acidosis and slightly shifted to the right by intracellular alkalosis (Fig. 6A).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 6.   Influence of pHi and lubeluzole on the inactivation of iLVA. The 10-s conditioning prepulse was varied from -60 to -120 mV, with the 155-ms test pulse maintained at -50 mV. For each test solution, the curve of the amplitudes of iLVA (I) was fitted as a function of the potential (V) of the conditioning prepulse in accordance with the Boltzmann equation I = Imax/(1 + exp((V - Vh)/Sl)), which yielded the parameters Imax, Vh, and Sl, where Imax is the amplitude of iLVA in the absence of inactivation, Vh is the conditioning potential at which the inactivation was half-maximal, and Sl is the slope factor. The iLVA values measured and the fitted curves were normalized by division by the individual Imax. The results are presented as mean ± S.E. A, influence of pHi on the inactivation of iLVA, measured 10 min after the patch was broken in the absence of lubeluzole. Vh (mV), Sl (mV), and the current density of Imax (pA/pF) were -91.7 ± 1.1, 5.0 ± 0.1, and -77 ± 13, respectively, at pHi 6 (n = 6); -87.6 ± 0.9, 4.8 ± 0.1, and -117 ± 9 at pHi 6.6 (n = 16); -82.3 ± 1.1, 5.1 ± 0.2, and -87 ± 8 at pHi 7.2 (n = 13); and -77.1 ± 1.2, 4.0 ± 0.1, and -118 ± 20 at pHi 9 (n = 6). These findings show that the Vh of iLVA was more negative at a lower pHi (P < .0001). B, the ratio of Imax after 5 min of extracellular application of 1 µM lubeluzole to Imax in the control solution is shown as a function of pHi. C, influence of 1 µM lubeluzole on the inactivation gating of iLVA at pHi 6, 6.6, 7.2, and 9. The curves are normalized by division by Imax. At 5 min after extracellular application of 1 µM lubeluzole, Vh (mV), Sl (mV), and the current density of Imax (pA/pF) were -101.3 ± 1.2, 6.0 ± 0.2, and -32 ± 7, respectively, at pHi 6 (n = 6); -97.6 ± 1.0, 6.5 ± 0.2, and -53 ± 7 at pHi 6.6 (n = 16); -88.6 ± 1.0, 6.2 ± 0.2, and -51 ± 6 at pHi 7.2 (n = 13); and -82.8 ± 1.6, 5.2 ± 0.2, and -78 ± 13 at pHi 9 ( = 6). At all tested pHi values lubeluzole produced a significant negative shift in Vh, an increase in Sl and a reduction in Imax (two-sided paired t test). The lubeluzole-induced change in Vh and ratio Imax were pHi dependent and larger at lower pHi (P < .0001).

Lubeluzole (1 µM) induced a negative shift of the inactivation curve at pHi 6, 6.6, 7.2, and 9 (Fig. 6C), which extends our previous findings at pHi 7.2 (Marrannes et al., 1998b). The effect of 1 µM lubeluzole on the half-inactivation potential (Vh) and the maximal iLVA in the absence of inactivation (Imax) was greater at pHi 6 and 6.6 than at pHi 7.2 and 9 (Fig. 6, B and C). At a constant conditioning potential of -100 mV, the lubeluzole-induced negative shift of the inactivation curve of iLVA caused a greater drop in the normalized iLVA at pHi 6 than at pHi 7.2 and 9 (Fig. 6C). This partly explains the pHi dependence of the block of iLVA by lubeluzole. However, this is to a large extent the consequence of the pHi dependence of Vh in the absence of lubeluzole. The more extensive decrease of Imax by lubeluzole at pHi 6 than at pHi 9 (Fig. 6B) indicates that the difference in block of iLVA by lubeluzole at different pHi values cannot be explained solely by a pHi-dependent shift in Vh. However, the difference in the effect of lubeluzole on Imax between pHi 6 and 9 was smaller than would be expected with a 1000-fold difference in [HL+]i (Table 1). Also, the lubeluzole-induced negative shift in Vh was not very much smaller at higher pHi. This suggests that intracellular HL+ plays only a moderate role in the block of iLVA.

Influence of the Uncharged Form of Lubeluzole on iLVA and iHVA. To isolate the contribution of L to the block of iLVA and iHVA, the influence of lubeluzole was tested at pHo 9 and pHi 9, at which [HL+]o and [HL+]i are reduced (Table 1; Fig. 7). At 5 min after application of 3 µM lubeluzole at pHo 9 and pHi 9, rLVA, rHVApeak, and rHVAend were decreased to 0.502 ± 0.093, 0.758 ± 0.038, and 0.598 ± 0.057, respectively (mean ± S.D., n = 4). This suggests that also L can contribute to some extent to the block of iLVA and iHVA. However, at normal pHo 7.4 the contribution of L to the block should be smaller than at pHo 9, at which [L] is 2.5 times higher.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Contribution of the uncharged form of lubeluzole to the block: influence of 3 µM lubeluzole at pHo 9 and pHi 9. A, voltages applied and sweeps in the control solution and every 30 s up to 5 min after application of 3 µM lubeluzole. The numbers in parentheses refer to the time point at which the sweeps were recorded, as shown in B and C. B, time course of the difference between the peak inward current and the current at the end of the 200-ms test pulse to -50 mV (iLVA), the peak current at the 155-ms test pulse to -20 mV (iHVApeak) and the current at the end of the test pulse to -20 mV (iHVAend). C, current ratios rLVA, rHVApeak, and rHVAend. To obtain these ratios, the time courses of iLVA, iHVApeak, and iHVAend in the control period were fitted exponentially and extrapolated to the end of the experiment. Division of each measured current amplitude by the value of the corresponding calculated curve obtained by fitting, at the same time point, yielded the ratios. This was done to quantify the effect of lubeluzole in the presence of continuous run-down of the Ba2+ currents. Same cell as in A and B.

Influence of Variation of Both pHo and pHi on the Block of Ca2+ Channels by Lubeluzole. We also tested whether lubeluzole blocks iLVA and iHVA to a different degree when both pHo and pHi are reduced, as is the case in ischemia (Lipton, 1999). At pHo 6.8/pHi 6.6 lubeluzole blocked iLVA and iHVA more than at pHo 7.4/pHi 7.2 with the same nominal transmembrane pH gradient (P < .01; unpaired two-sided t test) (Fig. 8).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 8.   Influence of pHo and pHi on the block of iLVA and iHVA by lubeluzole. The histograms show rLVA, rHVApeak, and rHVAend after 5-min application of 3 µM lubeluzole at different combinations of pHo and pHi. On the abscissa, pHo 6.8/pHi 6.6 stands for measurements at pHo 6.8 and simultaneously pHi 6.6. The first two combinations were at a constant pHo of 6.8. The next four combinations were at a constant pHo of 7.4. The last two combinations were at a constant pHo of 9. Results are expressed as mean ± S.E. The number of cells tested is given in parentheses.

At constant pHi, the block of iLVA was smaller at higher pHo, at which [HL+]o was lower. At constant pHo 7.4, the block of iLVA, iHVApeak, and iHVAend was clearly pHi dependent (P < .0001) and greater at lower pHi. This was also true for the moderately low pHi 6.6. The pHi dependence of the block was most pronounced for iHVAend because the acceleration of the apparent inactivation of iHVA was very dependent on pHi. A similar dependence of the block of iLVA and iHVA on pHi was also observed at constant pHo 6.8 and at constant pHo 9.

Application of Lubeluzole via the Patch Electrode. As another method of testing whether lubeluzole affects Ca2+ channels via the intracellular side of the cell membrane, 10 µM lubeluzole or the corresponding solvent (DMSO) was added to the electrode solution (pHi 7.2 and pHo 7.4). In these experiments the cells were stimulated with a 200-ms pulse to -50 mV, followed by a 155-ms pulse to -20 mV, every 30 s after entry into the whole-cell mode. The LVA and HVA Ba2+ current of DRG cells to which 10 µM lubeluzole was applied via the microelectrode alone (Fig. 9A) (n = 11) was difficult to distinguish from that of cells measured with the normal pipette solution (n = 8) or a solution containing 0.1% DMSO in addition (n = 4). Intracellular application of lubeluzole via the microelectrode tended to produce only a small acceleration of the apparent inactivation of iHVA, if any (Fig. 9A), in comparison with cells in which no lubeluzole was added to the microelectrode (Fig. 2A). In contrast, extracellular application of 10 µM lubeluzole to the same cells produced a pronounced block of iLVA and iHVA (Fig. 9, B-D).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 9.   Influence of application of 10 µM lubeluzole via the patch electrode and via the extracellular solution. A, activation of iHVA 10 min after entry into the whole-cell mode, with 10 µM lubeluzole in the electrode and no lubeluzole in the extracellular solution. From a -100-mV HP, a 200-ms test pulse to -50 mV was given to elicit and inactivate iLVA nearly completely. Thereafter, 155-ms test pulses varying from -50 to +10 mV were given to activate iHVA. The sweep interval was 20 s. Rs = 3.1 MOmega ; Cm = 58.8 pF. B, same cell as in A. In contrast to intracellular application of 10 µM lubeluzole alone, extracellular application of 10 µM lubeluzole produced a pronounced block of iLVA and iHVA. Every 30 s the shown pulse sequence was given. The last sweep in the control solution is shown together with the first 10 sweeps in the presence of 10 µM lubeluzole. Lubeluzole was applied immediately after the last sweep in the control solution. C, activation of iHVA after 5-min extracellular application of 10 µM lubeluzole to the same cell. D, I-V relationships of iHVA derived from the sweeps in A and C. Filled symbols: peak inward current. Unfilled symbols: current at the end of the 155-ms test pulse to -20 mV.

The observation that intracellular application of lubeluzole had only minimal effects on iLVA and iHVA does not necessarily mean that the effects of lubeluzole on Ca2+ channels are mainly extracellular. This observation could be explained by a rapid disappearance of the lipophilic uncharged form of lubeluzole via the cell membrane, which keeps its concentration low in and around the cell membrane. Even when an acidic microelectrode solution of pHi 6 was used (to reduce the efflux of the uncharged lubeluzole via the cell membrane) and also smaller cells (25-30 µm) and electrodes with a lower series resistance (1 MOmega , to facilitate the influx of lubeluzole into the cell via the electrode), the apparent inactivation of iHVA was still much slower than after extracellular application of 10 µM lubeluzole. This suggests that the membrane permeability for L must be high, as predicted by its high octanol/water partition ratio (104.9). The apparent inactivation of iHVA was quantified as the ratio (iHVApeak - iHVAend)/iHVApeak. In the absence of extracellular lubeluzole, this ratio was higher after intracellular application of 10 µM lubeluzole at pHi 6 (0.312 ± 0.098, mean ± S.D., n = 6) than after intracellular application of the same electrode solution without lubeluzole (0.187 ± 0.030, n = 7; P < .01, two-sided unpaired t test) in cells of a similar size. This is consistent with the hypothesis that intracellular HL+ accelerates the apparent inactivation of iHVA.

Extracellular and Intracellular Application of a Quaternary Ammonium Derivative of Lubeluzole. To avoid the complication arising from transmembrane diffusion of the uncharged form, a methyliodide quaternary ammonium derivative of lubeluzole (R133121) (Fig. 1) was synthesized and used, on the assumption that such a permanently charged compound would not be able to cross the cell membrane. If extracellular application of R133121 produced the same effects as lubeluzole, this would suggest that lubeluzole blocks Ca2+ channels from the extracellular side.

A pulse sequence consisting of a 200-ms test pulse to -50 mV followed by a 155-ms test pulse to -20 mV was given every 30 s (pHo 7.4/pHi 7.2). Extracellular application of R133121 for 5 min blocked iLVA reversibly by 36 ± 6% at 3 µM (mean ± S.D., n = 5), 63 ± 6% at 10 µM (n = 10), and 87.5 ± 2.3% at 30 µM (n = 6). R133121 (100 µM) blocked iLVA completely (n = 5). This corresponds to an IC50 of 5.6 µM, which is greater than the IC50 of lubeluzole for iLVA (1.2 µM) (Marrannes et al., 1998b). R133121 (30 µM) blocked iHVApeak by 15.2 ± 5.2% (mean ± S.D., n = 6). The LVA and HVA Ba2+ current and the holding current remained stable after 5 min of application of 30 µM R133121. In contrast, with 100 µM R133121 iHVA decreased progressively (Fig. 10F) and after a few minutes the holding current started to become very negative in most cells. Extracellular application of R133121 did not accelerate the apparent inactivation of iHVA, not even with 30 or 100 µM (Fig. 10, E and F).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 10.   Influence of intracellular and extracellular application of 100 µM R133121. A, time course of iLVA, iHVApeak, and iHVAend from the establishment of the whole-cell configuration. DMSO (1%) was added to the standard microelectrode solution (pHi 7.2/pHo 7.4). The stimulation sequence shown in E was given every 30 s. Rs = 2.2 MOmega ; Cm = 46.3 pF. B, same stimulation protocol in another cell with an electrode solution to which 100 µM R133121 (+1% DMSO) was added (pHi 7.2/pHo 7.4). Rs = 3.0 MOmega ; Cm = 42.7 pF. C, activation of iHVA 10 min after establishment of the whole-cell configuration with an electrode containing 1% DMSO. After a 200-ms prepulse to -50 mV 155-ms test pulses varying from -50 to +10 mV were given every 20 s. Same cell as in A. D, activation of iHVA 10 min after establishment of the whole-cell configuration with an electrode containing 100 µM R133121 (+1% DMSO). Same cell as in B. The apparent inactivation of iHVA was accelerated with 100 µM R133121 in the electrode. E, influence of extracellular application of 30 µM R133121 for 5 min, and thereafter 100 µM R133121 for 2.5 min. The electrode solution contained neither DMSO nor R133121. F, influence of extracellular application of 100 µM R133121 17 min after establishment of the whole-cell mode with an electrode containing 100 µM R133121 (+1% DMSO). Same cell as in B and D. The cell was stimulated every 30 s. The graph shows the last sweep in the extracellular control solution (to which 1% DMSO had been added) and the first six sweeps after the switch to an extracellular solution containing 100 µM R133121 (+1% DMSO). In contrast to intracellular application, extracellular application of even the very high concentration of 100 µM R133121 was not able to accelerate the apparent inactivation of iHVA.

The effects of intracellular application of 10 µM R133121 on Ca2+ channels were small (n = 13) (data not shown). Little or no acceleration of the apparent inactivation of iHVA could be seen at this concentration of R133121. At 10 min after intracellular application of 100 µM R133121 (+1% DMSO) the current densities of iLVA, iHVApeak, and iHVAend (60 ± 26, 115 ± 35, and 93 ± 30 pA/pF, respectively, n = 11) were smaller than after 10 min with a microelectrode solution containing 1% DMSO (115 ± 40, 171 ± 56, and 144 ± 45 pA/pF, respectively, n = 7; P = .002, .017, and .011, two-sided unpaired t test) (Fig. 10, A and B). These measurements were carried out in cells with a very similar diameter (±38 µm). It is remarkable that intracellular application of 100 µM R133121 blocked iLVA much less than extracellular application of 100 µM R133121, which blocked iLVA completely.

In most cells to which 100 µM R133121 (+1% DMSO) was applied via the microelectrode the rate of the apparent inactivation of iHVA was increased with respect to control cells with 1% DMSO added to the microelectrode solution (Fig. 10, C and D). This acceleration was voltage dependent and higher at a -10-mV test pulse than at -20 mV, and generally there was no acceleration at -30 mV. In contrast, after extracellular application of 3 µM lubeluzole this rate was already clearly accelerated at -30 mV (Fig. 2C). The rate of the apparent inactivation of iHVA after intracellular application of 100 µM R133121 was similar to or smaller than that after extracellular application of 3 µM lubeluzole, after which [HL+]i would be expected to approach 3 µM (Table 1). Consequently, R133121 was much less potent than lubeluzole in accelerating the apparent inactivation of iHVA.

Additional extracellular application of the very high concentration of 100 µM R133121 after intracellular application of 100 µM R133121 did not further accelerate the apparent inactivation of iHVA (Fig. 10F). That rather intracellular application of R133121, and not extracellular application, accelerated the apparent inactivation of iHVA supports our conclusion (from the lubeluzole experiments at different pHi) that lubeluzole accelerates the apparent inactivation of iHVA by an effect of HL+ acting from the intracellular side.

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The experiments extend our earlier observations that lubeluzole blocks iLVA and iHVA (Marrannes et al., 1998b). The results presented in this article show the following: 1) the effects of lubeluzole on Ca2+ channels depend on pHo and pHi; 2) application of lubeluzole via the patch electrode blocks iLVA and iHVA only minimally in comparison with extracellular application; and 3) extracellular and intracellular application of the less potent quaternary ammonium derivative R133121 block iLVA and iHVA.

Influence of pH on Ca2+ Channels. The observed influence of pHo on iLVA and iHVA, and the pHi-dependent shift of the activation curve of iHVA agree with earlier findings with other cell types (Kaibara and Kameyama, 1988; Prod'Hom et al., 1989; Tytgat et al., 1990; Tombaugh and Somjen, 1996; Zhou and Jones, 1996). Previous studies reported that iLVA of heart cells (Tytgat et al., 1990) and hippocampal neurons (Tombaugh and Somjen, 1997) was not influenced by pHi. However, we found a clear dependence of the half-inactivation potential of iLVA of DRG cells on pHi, probably due to a change in intracellular surface potential of the cell membrane and T-channel (Hille, 1992).

Site of Action of Lubeluzole on iLVA. Lubeluzole clearly blocked iLVA at pHo 6. Because at pHo 6 97.5% of the extracellular lubeluzole is in the protonated form and the predicted [HL+]i is low, this suggests that HL+ can block iLVA from the extracellular side. That no intracellular penetration of lubeluzole is needed to achieve block of iLVA is supported by the observation that extracellular application of the quaternary ammonium derivative of lubeluzole (R133121) also blocks iLVA. After switching pHo from 9 to 7.4 in the continuous presence of lubeluzole, the relative change in iLVA was greater than after a pHo change of the same magnitude in the absence of lubeluzole. This indicates that a rapid replacement of extracellular L by HL+ increased the block of iLVA, and consequently that extracellular HL+ blocks iLVA more than L.

At constant pHi the block of iLVA was not very much smaller at higher pHo (lower [HL+]o) (Fig. 8). This may be explained partly by the fact that the Vh of iLVA is more negative at higher pHo (Tytgat et al., 1990; Tombaugh and Somjen, 1996). This influences the impact of a drug-induced negative shift of Vh on the amplitude of iLVA, measured at a constant -100 mV HP, and partly counteracts the effect of the pHo-related difference in [HL+]o on the block of iLVA. In addition, there are arguments that lubeluzole blocks iLVA not only via extracellular HL+. The observation that iLVA is also blocked at pHo 9/pHi 9, at which both [HL+]o and [HL+]i are low, suggests that also L is able to contribute to the block. At constant pHo 7.4, lubeluzole blocked iLVA more at lower pHi. This can be explained partly by the more negative half-inactivation potential of iLVA at lower pHi; then a lubeluzole-induced negative shift in Vh produces a larger decrease in iLVA, elicited from a -100-mV HP. This explanation on its own is not an argument for a contribution of intracellular HL+ to the block. However, the lubeluzole-induced reduction of Imax and negative shift of Vh were also greater at lower pHi, which indicates that intracellular HL+ contributes to the block of iLVA. The fact that the pHi dependence of the latter two effects was not very pronounced, considering the 1000-fold predicted variation of [HL+]i between pHi 6 and 9, suggests that iLVA is not only blocked via intracellular HL+ and corresponds with a contribution of L and extracellular HL+ to the block of iLVA.

Site of Action of Lubeluzole on iHVA. The partial block of the peak amplitude of iHVA by 3 µM lubeluzole at pHo 6 and after extracellular application of 30 µM R133121 suggest that extracellular HL+ contributes somewhat to the block of iHVA. That iHVA is also blocked partly by 3 µM lubeluzole at pHo 9/pHi 9 suggests that L may contribute to the block, as well.

Several lines of evidence indicate that the acceleration of the apparent inactivation of iHVA by lubeluzole is caused little or not at all by an extracellular effect of HL+: 1) such an acceleration was only minimal when lubeluzole was given at pHo 6/pHi 7.2 (at which [HL+]o is high and [L] and [HL+]i are low); 2) a sudden decrease of pHo from 9 to 7.4 in the continuous presence of lubeluzole, and thus a rapid extracellular replacement of L by HL+, did not augment the acceleration of the apparent inactivation; and 3) extracellular application of R133121 did not induce such an acceleration as seen with lubeluzole; the slight acceleration of the apparent inactivation of iHVA after application of 3 µM lubeluzole at pHo 9/pHi 9 suggests that L can contribute to this acceleration.

The pronounced dependence of the acceleration of the apparent inactivation of iHVA by lubeluzole on pHi, in parallel with the corresponding [HL+]i, suggests that intracellular HL+ (or HL+ that accumulates intracellularly with its lipophilic tail within the membrane) plays an important role herein. The acceleration of the apparent inactivation of iHVA by lubeluzole was also more pronounced at test potentials at which iHVA was more activated. These experiments are consistent with an open channel block of iHVA or a destabilization of the open channel state by HL+ acting from the intracellular side. The experiments with extracellular and intracellular application of R133121 support this conclusion. Interestingly, R133121 is much less potent than lubeluzole in accelerating the apparent inactivation of iHVA, and it is also less potent in blocking iLVA. This indicates that the added methyl group on the nitrogen of the piperidine ring changes the molecule at a site critical for the open channel block of iHVA by lubeluzole and for the block of iLVA. This nitrogen is the same as the one that is protonated first in lubeluzole. The methyl group may induce some sterical hindrance to approach or bind Ca2+ channels. Alternatively, lubeluzole may diffuse within the cell membrane to the binding site in the uncharged form (Rhodes et al., 1985), and thereafter protrude with the protonated nitrogen in a more polar environment. That a quaternary ammonium derivative of a compound, after both extracellular and intracellular application, is less potent than the original tertiary ammonium compound has also been observed for the L-type Ca2+ current (Leblanc and Hume, 1989; Kwan et al., 1995; Watanabe et al., 1995; Wegener and Nawrath, 1995) and for K+ currents (Kirsch and Narahashi, 1983; Howe and Ritchie, 1991; Wegener and Nawrath, 1996).

Several other piperidine derivatives block HVA Ca2+ channels (Gould et al., 1983; Grantham et al., 1994; Sah and Bean, 1994; Zamponi et al., 1996) and bind to a high-affinity site on the L-type Ca2+ channel (King et al., 1989). DRG cells have been reported to express L-, N-, P-, Q-, and possibly also R-type HVA Ca2+ channel currents, depending on the cell size (Mintz et al., 1992; Scroggs and Fox, 1992; Diochot et al., 1995). Because low pHi augmented the lubeluzole-induced acceleration of the apparent inactivation of iHVA, not only in medium-sized DRG neurons but also in small DRG neurons that express more L-type Ca2+ current, intracellular HL+ probably accelerates the apparent inactivation of iHVA of all types of Ca2+ channels contributing to iHVA in these DRG cells. Interestingly, the inactivation of iLVA is not accelerated by lubeluzole (Marrannes et al., 1998b) and the lubeluzole-induced reduction in iLVA is much less affected by pHi than that in iHVAend. This suggests that intracellular HL+ affects iLVA and iHVA differently.

Extracellular versus Intracellular Application of Lubeluzole. Application of lubeluzole via the patch electrode in the whole-cell recording configuration had only minimal effects on iLVA and iHVA in comparison with extracellular application. As shown by the other experiments in this article, this does not necessarily mean that L and HL+ block Ca2+ channels only from the extracellular side; the effect after intracellular application may have been small because of efflux of L, resulting in a low concentration of lubeluzole in and near the cell membrane. The membrane permeability of L is probably high owing to its high lipophilicity (octanol/water partition ratio = 104.8) (Harris, 1960) and 28% of lubeluzole is in the uncharged form at pHi 7.2. Because of the easy efflux of L via the large surface area of the cell membrane, the steady state concentrations of L in the cell membrane and [HL+]i just below the membrane remained probably low and were determined more by the extracellular lubeluzole concentration than by that of the solution in the electrode, which communicated with the membrane via the much smaller area of the electrode tip and via a longer diffusional pathway than the transmembrane diffusion distance.

In conclusion, the experiments suggest that lubeluzole blocks Ca2+ channels from both the extracellular and the intracellular side in a pH-dependent manner, and that intracellular HL+ affects iLVA and iHVA differently. The experiments also point at the importance of the region of the piperidene nitrogen atom for the block of Ca2+ channels by lubeluzole.

    Acknowledgments

We thank R. Stokbroekx for the chemical synthesis of R133121, C. Verellen for secretarial assistance, and M. De Ryck, A. Hermans and J. Lubin for helpful comments on the manuscript.

    Footnotes

Accepted for publication July 3, 2000.

Received for publication April 12, 2000.

Send reprint requests to: Dr. R. Marrannes, Central Nervous System Discovery Research, Janssen Research Foundation, B-2340 Beerse, Belgium. E-mail: rmarrann{at}janbe.jnj.com

    Abbreviations

iLVA, low-voltage-activated Ca2+ channel current; iHVA, high-voltage-activated Ca2+ channel current; HL+, protonated form of lubeluzole; L, uncharged form of lubeluzole; T, total lubeluzole; pHo, extracellular pH; pHi, intracellular pH; DRG, dorsal root ganglion; DMEM, Dulbecco's modified Eagle's medium; DMSO, dimethyl sulfoxide; HP, holding potential; rLVA, fraction of iLVA left after block by a compound; rHVA, fraction of iHVA left after block; HEPES, N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]; MES, 2-[N-morpholino]ethanesulfonic acid; Vh, half-inactivation potential; Rs, series resistance; Cm, membrane capacitance.

    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References


0022-3565/00/2952-0531$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marrannes, R.
Right arrow Articles by De Prins, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marrannes, R.
Right arrow Articles by De Prins, E.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition